Lexi-Interact Severity Classification Reference
This reference guide provides common drug interaction examples classified by Lexicomp severity ratings. For comprehensive interaction checking, use clinical decision support software (Lexicomp, Micromedex, Clinical Pharmacology). This is not a substitute for professional interaction screening tools.
Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions.
Interaction is unlikely, of limited clinical significance, or management is not typically needed.
Monitor patients for signs/symptoms of interaction. Dose adjustments may be needed but are not required in most cases.
Assess risk/benefit ratio. Use alternative agents when possible. If used together, dose adjustment or close monitoring required.
Risk of interaction outweighs benefit. Combination is contraindicated. Do not use together.
warfarin + nsaid
NSAIDs increase bleeding risk when combined with warfarin
Severity: Major - Consider Alternative
Clinical Significance:
NSAIDs inhibit platelet function and may cause GI bleeding. Combined with warfarin, this significantly increases hemorrhage risk. INR may also increase.
Management:
Avoid combination if possible. If necessary, use lowest NSAID dose for shortest duration, monitor INR closely, and assess for bleeding signs.
simvastatin + clarithromycin
Clarithromycin significantly increases simvastatin levels, causing severe myopathy risk
Severity: Contraindicated - Do Not Use
Clinical Significance:
CYP3A4 inhibition by clarithromycin increases simvastatin exposure up to 10-fold, greatly increasing rhabdomyolysis risk.
Management:
Contraindicated. Discontinue simvastatin during clarithromycin therapy or use alternative antibiotic (e.g., azithromycin) or statin (e.g., pravastatin).
lisinopril + potassium
ACE inhibitors combined with potassium supplements increase hyperkalemia risk
Severity: Moderate - Monitor Closely
Clinical Significance:
Both agents increase serum potassium. Combined use may result in clinically significant hyperkalemia, especially in patients with renal impairment.
Management:
Monitor serum potassium regularly. Use potassium supplements cautiously and only if clearly needed. Consider dietary potassium instead.
metformin + contrast
Iodinated contrast with metformin increases lactic acidosis risk
Severity: Major - Consider Alternative
Clinical Significance:
Contrast-induced nephropathy may impair metformin clearance, leading to accumulation and potentially fatal lactic acidosis.
Management:
Discontinue metformin at time of or before contrast procedure in patients with eGFR 30-60. Restart 48 hours after if renal function stable.
fluconazole + warfarin
Fluconazole inhibits warfarin metabolism, significantly increasing INR
Severity: Major - Consider Alternative
Clinical Significance:
CYP2C9 inhibition by fluconazole increases warfarin exposure, often doubling INR within 3-5 days. Severe bleeding risk.
Management:
Reduce warfarin dose by 25-50% when starting fluconazole. Monitor INR closely (after 3-4 days, then weekly). Resume usual dose after fluconazole discontinued.
methotrexate + trimethoprim
Both agents cause folate antagonism, increasing bone marrow suppression
Severity: Major - Consider Alternative
Clinical Significance:
Additive folate antagonism increases risk of severe pancytopenia, mucositis, and hepatotoxicity.
Management:
Avoid combination. If unavoidable, reduce methotrexate dose, provide leucovorin rescue, and monitor CBC closely.
digoxin + amiodarone
Amiodarone increases digoxin levels and enhances AV block risk
Severity: Major - Consider Alternative
Clinical Significance:
P-glycoprotein inhibition by amiodarone doubles digoxin levels. Both drugs slow AV conduction, increasing bradycardia risk.
Management:
Reduce digoxin dose by 50% when starting amiodarone. Monitor digoxin levels after 1 week. Check ECG for bradycardia.
ssri + tramadol
Combined use increases serotonin syndrome and seizure risk
Severity: Moderate - Monitor Closely
Clinical Significance:
Additive serotonergic effects may precipitate serotonin syndrome. Both agents also lower seizure threshold.
Management:
Use combination cautiously. Educate patient on serotonin syndrome symptoms. Monitor for tremor, agitation, confusion, hyperthermia.
Important Disclaimer
This is a reference guide showing common examples only. Comprehensive interaction screening requires clinical decision support software that evaluates the complete medication list, doses, and patient-specific factors. Always use FDA-approved interaction checking tools (Lexicomp, Micromedex, First Databank) before dispensing medications. This tool is for educational purposes and must not be used as a substitute for professional drug interaction screening.
QTc Prolongation (Risk Rating D or X)
Multiple QT-prolonging agents: antipsychotics + azole antifungals, macrolides + class III antiarrhythmics, ondansetron + fluoroquinolones. Monitor ECG and electrolytes.
Serotonin Syndrome (Risk Rating C-D)
SSRI + MAOI (X), SSRI + tramadol (C), SSRI + linezolid (D), SSRI + triptans (C). Watch for agitation, tremor, hyperthermia, hyperreflexia.
Nephrotoxicity (Risk Rating C-D)
NSAID + ACE inhibitor + diuretic (triple whammy), aminoglycoside + vancomycin, NSAID + lithium. Monitor renal function and drug levels.
Anticoagulation Enhancement (Risk Rating D)
Warfarin + antibiotics (especially fluoroquinolones, metronidazole, TMP-SMX), warfarin + antifungals, DOACs + strong CYP3A4 inhibitors. Monitor INR or anti-Xa levels.
CNS Depression (Risk Rating C-D)
Opioid + benzodiazepine (D), opioid + gabapentinoid (D), multiple sedatives. Assess for respiratory depression, avoid if possible.
Embed This Calculator on Your Website
Add this free calculator to your blog, website, or CMS with a simple copy-paste embed code.
Introduction
Adverse drug events caused by drug-drug interactions (DDIs) result in approximately 125,000 deaths and 350,000 hospitalizations annually in the United States, according to data cited by the Office of Disease Prevention and Health Promotion. The majority of serious DDIs are not obscure. The top 10 clinically significant interactions (warfarin with NSAIDs, warfarin with fluoroquinolones, ACE inhibitors with potassium-sparing diuretics, statins with CYP3A4 inhibitors, metformin with contrast media, MAOIs with serotonergic agents, QT-prolonging drug combinations, opioids with benzodiazepines, anticoagulants with antiplatelet agents, and nephrotoxin combinations) account for a disproportionate share of preventable DDI harm. Pharmacists and prescribers who routinely review medication lists for these interactions prevent documented patient harm every day. This reference tool provides severity classifications and clinical management guidance for high-priority drug interactions.
What This Calculator Does
This reference tool provides a structured severity classification system for drug-drug interactions based on the three-tier framework used by clinical decision support systems: Contraindicated (do not use together), Major (significant risk; requires prescriber intervention or alternative), and Moderate (requires monitoring or dose adjustment). For each interaction category, it provides the pharmacodynamic or pharmacokinetic mechanism, clinical consequence, and recommended management action. It is designed as a quick reference for clinical pharmacists, pharmacy students, and prescribers reviewing polypharmacy regimens.
The Formula
Drug interaction severity classifications are based on three variables: the probability that the interaction will occur (pharmacokinetic predictability), the clinical significance of the adverse outcome if it does occur (severity of potential harm), and the availability of management options that mitigate risk. A Contraindicated interaction means no safe co-administration option exists. A Major interaction requires active clinical management (prescriber notification, therapeutic substitution, or protocol-level monitoring). A Moderate interaction warrants monitoring but may not require immediate intervention. Mechanism categories are pharmacokinetic (CYP enzyme inhibition/induction, P-glycoprotein effects, renal transporter effects) or pharmacodynamic (additive toxicity such as QT prolongation, additive efficacy leading to toxicity such as bleeding risk, or opposing effects).
Step-by-Step Example
Identify all medications in the regimen
Include prescription drugs, over-the-counter medications, herbals, and supplements. Common clinically significant OTC interactions include: aspirin with warfarin (bleeding), St. John's Wort with cyclosporine or HIV antiretrovirals (CYP3A4 induction, reduced drug levels), and melatonin with anticoagulants (modest antiplatelet effect). Review the complete medication list, not just the newly added drug.
Identify interaction pairs and mechanism
Example: Patient on warfarin (narrow therapeutic index anticoagulant) newly prescribed ciprofloxacin (fluoroquinolone antibiotic). Mechanism: ciprofloxacin inhibits CYP1A2 and CYP3A4, which metabolize the R-warfarin enantiomer, increasing warfarin plasma levels by 15% to 35%. This is a Major interaction requiring INR monitoring within 3 to 5 days of starting the antibiotic, with likely warfarin dose reduction.
Apply severity classification and management action
Contraindicated example: MAO inhibitor + serotonergic agent (SSRI, tramadol, meperidine). Risk: serotonin syndrome, potentially fatal. Management: 14-day washout between MAOI and serotonergic agents (5 weeks if transitioning from fluoxetine due to long half-life). Major example: simvastatin + clarithromycin. Risk: CYP3A4 inhibition leading to 10-fold simvastatin AUC increase, rhabdomyolysis. Management: hold simvastatin during antibiotic course or use azithromycin as CYP3A4-neutral alternative.
Document and communicate the interaction
For Major or Contraindicated interactions: document the interaction, clinical risk, and management recommendation in the patient's pharmacy profile and communication to the prescriber. For Moderate interactions: document monitoring parameters (what to check, when to check) and the threshold for clinical intervention. Undocumented interactions that result in patient harm expose the pharmacy to liability regardless of whether an alert was generated.
Real-World Use Cases
Polypharmacy Regimen Review for an Elderly Patient
A 79-year-old patient on 11 medications presents for a medication therapy management (MTM) review. The pharmacist systematically checks all pairwise combinations. Flagged interactions: (1) Amiodarone + warfarin: Major, CYP2C9 inhibition increases warfarin levels by 30% to 50%, INR monitoring required; (2) Lisinopril + spironolactone: Major, hyperkalemia risk, potassium monitoring required; (3) Metformin + furosemide: Moderate, diuretic can impair renal function and increase metformin accumulation risk, monitor CrCl. Three actionable interactions identified from 55 possible pairwise combinations.
Pre-Discharge Medication Reconciliation
A hospital pharmacist reviews discharge medications for a cardiac surgery patient being discharged on new anticoagulation. New interaction identified: rivaroxaban (direct oral anticoagulant) + amiodarone (P-glycoprotein inhibitor). Mechanism: amiodarone inhibits P-gp-mediated rivaroxaban efflux, increasing rivaroxaban exposure by approximately 50%. Severity: Major. Management: reduce rivaroxaban dose for lower CrCl patients; monitor for bleeding signs; discuss with the prescriber before discharge.
Retail Pharmacy New Prescription Interaction Alert
A retail pharmacist receives a new prescription for trazodone for a patient already on tramadol. Interaction: both have serotonergic activity. Severity: Major. Mechanism: additive serotonin syndrome risk, especially at higher doses or with rapid titration. The pharmacist contacts the prescriber, who is unaware the patient is on tramadol (from a different prescriber), and discusses either a non-serotonergic alternative for sleep or a dose reduction strategy with clear monitoring criteria.
Comparison
| Interaction Pair | Severity | Mechanism | Clinical Risk | Management |
|---|---|---|---|---|
| Warfarin + NSAIDs | Major | Pharmacodynamic (antiplatelet + anticoagulation) | GI bleeding, major hemorrhage | Avoid; use acetaminophen if analgesia needed |
| Statins + CYP3A4 inhibitors (clarithromycin, itraconazole) | Major/Contraindicated | CYP3A4 inhibition (10x AUC increase) | Rhabdomyolysis | Hold statin or use non-CYP3A4 statin (pravastatin, rosuvastatin) |
| MAOIs + SSRIs/SNRIs | Contraindicated | Pharmacodynamic (serotonin excess) | Serotonin syndrome (fatal risk) | 14-day washout; 5 weeks for fluoxetine |
| QT-prolonging drugs (azithromycin + ondansetron) | Major | Pharmacodynamic (additive QT prolongation) | Torsades de pointes, ventricular arrhythmia | Avoid combination; ECG monitoring if unavoidable |
| Opioids + Benzodiazepines | Major | Pharmacodynamic (additive CNS/respiratory depression) | Respiratory depression, death | Minimize concurrent use; naloxone prescription recommended |
| ACE inhibitors + K-sparing diuretics | Major | Pharmacodynamic (additive hyperkalemia) | Life-threatening hyperkalemia | Monitor potassium closely; avoid in renal impairment |
| Metformin + Nephrotoxic agents (NSAIDs, contrast) | Moderate-Major | PK (reduced renal elimination of metformin) | Lactic acidosis | Hold metformin 48h before/after contrast; avoid chronic NSAID use |
| Warfarin + Fluoroquinolones | Major | CYP1A2/3A4 inhibition (R-warfarin increase) | Supratherapeutic INR, bleeding | INR within 3-5 days; anticipate dose reduction |
Common Mistakes to Avoid
Dismissing moderate interactions as clinically unimportant. Moderate interactions require monitoring, not inaction. A moderate interaction in a low-risk patient (young, no organ impairment, single moderate interactor) may be manageable with education alone. The same moderate interaction in a high-risk patient (elderly, renal impairment, narrow therapeutic index drug) can be a major clinical event. Severity classification is a starting point for risk assessment, not a substitute for it.
Checking only the newly added drug against the existing regimen rather than checking all pairs. When a new drug is added to a regimen, it should be checked against each existing medication individually. But existing medications in a complex regimen may also interact with each other in ways that were previously missed or that have become newly relevant as doses changed.
Relying on automated alerts without understanding the mechanism. Clinical decision support systems generate interaction alerts for thousands of drug pairs, many of which are clinically irrelevant in context. Pharmacists who click through alerts without understanding the mechanism cannot distinguish a clinically significant alert from an alert that can safely be overridden. Mechanism knowledge is the skill; the alert system is the trigger.
Not considering patient-specific risk modifiers when classifying interaction severity. A drug interaction listed as Moderate may be Major in a patient with CrCl 15 mL/min, elevated bilirubin, or genetic CYP polymorphisms. Always apply the published interaction severity to the individual patient's pharmacokinetic and pharmacodynamic risk factors.
Frequently Asked Questions
Accuracy and Disclaimer
This drug interaction reference provides general clinical information about drug-drug interaction severity classifications based on established pharmacological literature and clinical pharmacology references including Lexicomp, Clinical Pharmacology, and peer-reviewed literature. This tool does not replace a comprehensive drug interaction database, clinical pharmacy review, or pharmacist judgment. Drug interaction significance is patient-specific and depends on dose, duration, patient health status, and concurrent risk factors. This reference is for use by qualified healthcare professionals only and does not constitute individualized medical or pharmaceutical advice. All clinical decisions should be verified against current prescribing information and made by a licensed healthcare provider.
Conclusion
Drug interaction checking is a mandatory step in every medication dispensing decision, and it is most effective when the reviewer understands the mechanism behind the interaction, not just that one exists. Mechanistic knowledge allows prediction of interaction severity based on patient-specific risk factors: a patient with CrCl 25 mL/min on metformin faces dramatically higher biguanide accumulation risk from nephrotoxic co-medications than a patient with CrCl 90 mL/min. Use the Creatinine Clearance Calculator to assess renal function in patients on renally-cleared medications before evaluating nephrotoxic combinations, and the Medication Adherence Rate Calculator to identify patients whose adherence patterns may indicate unrecognized drug interaction effects.
Related Pharmacy & Clinical Pharmacology Calculators
Creatinine Clearance (Cockcroft-Gault) Calculator
Calculate creatinine clearance for renal function assessment and drug dosing adjustment in patients with renal impairment using the Cockcroft-Gault equation with optional IBW/ABW adjustment for obese patients.
Use CalculatorPharmacy & Clinical PharmacologyAUC-Based Vancomycin Dosing Calculator
Calculate vancomycin dosing using 2020 ASHP/IDSA/SIDP AUC-guided monitoring guidelines with empiric first-dose and Bayesian two-level adjustment methods targeting AUC 400-600 mg·h/L.
Use CalculatorPharmacy & Clinical PharmacologyPharmacy Compounding Cost Calculator
Calculate accurate compounding prices including ingredient costs, pharmacist/technician labor, overhead allocation, supplies, profit margin, and dispensing fees for custom pharmaceutical preparations.
Use CalculatorPharmacy & Clinical PharmacologyMedication Adherence Rate Calculator
Calculate medication adherence using PDC (Proportion of Days Covered), MPR, or pill count methods with CMS Star Rating threshold analysis and MTM intervention recommendations.
Use CalculatorYou May Also Find Useful
Tax Calculator
Estimate your 2026 federal income tax based on filing status, gross income, deductions, and current tax brackets. See your marginal and effective tax rates instantly.
Use CalculatorFinance & AccountingSalary to Hourly Calculator
Convert your annual salary to an hourly wage instantly. Adjust for hours per week, weeks per year, and overtime to find your true hourly rate.
Use CalculatorFinance & AccountingCommission Calculator
Determine sales commissions based on revenue, rate tiers, and bonus structures.
Use Calculator